Profile data is unavailable for this security.
About the company
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
- Revenue in CHF (TTM)33.56m
- Net income in CHF-13.73m
- Incorporated1995
- Employees80.00
- LocationKuros Biosciences AGWagistrasse 25SCHLIEREN 8952SwitzerlandCHE
- Phone+41 447334747
- Fax+41 447334740
- Websitehttps://kurosbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Santhera Pharmaceuticals Holding AG | 103.38m | 54.78m | 117.03m | 46.00 | -- | 1.73 | -- | 1.13 | -17.28 | -17.28 | 9.14 | 5.34 | 1.19 | 3.37 | 63.69 | -- | 63.20 | -33.83 | 136.70 | -52.56 | 96.87 | 86.74 | 52.99 | -79.40 | 0.75 | 3.57 | 0.2628 | -- | 1,283.33 | 26.70 | 177.08 | -- | 1.87 | -- |
| Molecular Partners AG | 6.73m | -58.53m | 124.54m | 168.00 | -- | 0.6621 | -- | 18.52 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Newron Pharmaceuticals SpA | 8.96m | -16.04m | 187.93m | 23.00 | -- | -- | -- | 20.98 | -0.8991 | -0.8991 | 0.5019 | -1.66 | 0.2873 | -- | 4.57 | 389,414.50 | -51.45 | -37.10 | -111.53 | -43.98 | 94.80 | 91.72 | -179.13 | -270.48 | -- | -2.86 | 2.62 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Xlife Sciences AG | 988.44k | 14.88m | 194.48m | 17.00 | 28.00 | 0.7111 | 7.69 | 196.76 | 1.22 | 1.22 | 0.1382 | 47.95 | 0.002 | -- | 0.2044 | 58,143.53 | 1.85 | -- | 2.33 | -- | 45.43 | -- | 938.17 | -- | -- | -- | 0.1345 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Kuros Biosciences AG | 33.56m | -13.73m | 287.99m | 80.00 | -- | 5.06 | -- | 8.58 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| Idorsia Ltd | 141.42m | -55.88m | 411.19m | 938.00 | -- | -- | -- | 2.91 | -0.3534 | -0.3534 | 0.7363 | -4.97 | 0.1912 | 0.1645 | 113.09 | 150,766.50 | -7.56 | -46.72 | -12.46 | -53.84 | 93.05 | -- | -39.51 | -709.80 | 1.00 | -26.26 | 5.82 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Basilea Pharmaceutica AG Allschwil | 157.63m | 10.45m | 567.62m | 147.00 | 49.18 | -- | 47.10 | 3.60 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Polypeptide Group AG | 321.25m | -50.87m | 1.09bn | 1.20k | -- | 2.87 | -- | 3.38 | -1.54 | -1.54 | 9.70 | 11.43 | 0.5137 | 2.31 | 5.08 | 267,262.50 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| Cosmo Pharmaceuticals NV | 95.65m | 1.13m | 1.27bn | 325.00 | 1,025.82 | 2.75 | 82.11 | 13.25 | 0.0704 | 0.0704 | 5.93 | 26.29 | 0.1473 | 3.06 | 2.88 | 294,307.90 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Banque Pictet & Cie SAas of 11 Dec 2023 | 1.10m | 2.97% |
| Credit Suisse Asset Management (Schweiz) AGas of 16 Mar 2023 | 1.09m | 2.97% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 1.06m | 2.87% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 325.06k | 0.88% |
| UBS Asset Management Switzerland AGas of 07 May 2024 | 307.03k | 0.83% |
| BlackRock Investment Management (UK) Ltd.as of 30 Apr 2024 | 65.99k | 0.18% |
| Migros Bank AGas of 31 Dec 2023 | 65.13k | 0.18% |
| BlackRock Asset Management Schweiz AGas of 08 May 2024 | 53.56k | 0.15% |
| Equinor Asset Management ASAas of 31 Dec 2023 | 48.75k | 0.13% |
| Credit Suisse AGas of 31 Jan 2024 | 35.94k | 0.10% |
